Pharmacodynamics: Targets, Receptor Theory, Agonists and Antagonists

I. Pharmacodynamics (PD) – What Is It?

Essence: Pharmacodynamics is the science that studies the biological effects of drugs on the body and their mechanisms of action.
Focus: It answers the question “What does the drug do to the body?”, in contrast to pharmacokinetics, which asks “What does the body do to the drug?”.
Key object: The interaction between the drug and its target and the subsequent biological responses.

From a lactology perspective, pharmacodynamics is crucial because the same receptor-mediated effect that occurs in the mother may also occur in the breastfed infant if the drug reaches clinically relevant concentrations in breast milk and is orally bioavailable to the infant. Understanding the nature of the target and the intensity of the biological response helps clinicians anticipate potential adverse effects on the nursing infant (for example, sedation, respiratory depression or changes in prolactin-driven milk production).

II. Main Targets of Drug Action – Where Do Drugs Act?

Drugs exert their effects by interacting with specific molecular targets in the body. The most important targets are:

• Receptors (the most common target!)
• Enzymes
• Ion channels
• Transport systems (transporters)
• Other targets such as DNA/RNA or structural proteins.

From a breastfeeding safety point of view, knowing the target helps predict whether the infant may experience similar effects when exposed to small amounts of the drug via breast milk. For example, sedative drugs acting on central nervous system receptors or ion channels may cause drowsiness or hypotonia in the infant, whereas drugs acting locally in the gut with poor systemic absorption are less likely to produce systemic pharmacodynamic effects in the breastfed child.

1. Receptors – The Most Common Target

Receptors are specific proteins, most often located on the cell surface (membrane receptors), but sometimes inside the cell, including nuclear receptors.

Function: Receptors recognize natural signaling molecules such as hormones, neurotransmitters and growth factors (the so‑called endogenous ligands) and translate their binding into a cellular response. Drugs can either mimic (agonize) or block (antagonize) the actions of these endogenous ligands.

In lactology, receptor selectivity and potency are pivotal. For example:

• Dopamine receptor agonists can suppress prolactin and thus reduce milk production, even if only low maternal doses are used.
• Prolactin‑modulating drugs or oxytocin analogues may influence lactation physiology and milk ejection, which is clinically relevant for early breastfeeding support.

Therefore, when evaluating drug compatibility with breastfeeding, clinicians consider not only exposure (dose, milk concentration, infant age) but also receptor type, tissue distribution and expected pharmacodynamic response in the infant and in the mammary gland.

2. Enzymes as Drug Targets

Drugs can inhibit (most commonly) or activate (more rarely) specific enzymes.

Example: Angiotensin‑converting enzyme (ACE) inhibitors used for hypertension.

Enzyme inhibition in the mother may alter systemic hemodynamics, renal function or metabolic pathways, which can indirectly affect lactation (e.g. by changing blood pressure, electrolyte balance or maternal well‑being). For the infant, clinically significant enzyme inhibition usually requires substantial exposure, which is uncommon for many modern drugs with low milk transfer, but caution is needed in premature or medically fragile infants, where even modest pharmacodynamic effects may be important.

3. Ion Channels

Drugs can block or activate ion channels for Na⁺, K⁺, Ca²⁺ or Cl⁻, thereby modifying the electrical properties of excitable cells.

Examples:

• Local anaesthetics that block voltage‑gated Na⁺ channels.
• Calcium channel blockers for hypertension or angina.

In the context of breastfeeding, drugs acting on cardiac or neuronal ion channels may theoretically affect the infant’s heart rhythm or central nervous system excitability if sufficient drug reaches the infant. While many of these drugs are considered compatible with breastfeeding at usual doses, clinicians must monitor for signs such as poor feeding, lethargy, irritability or changes in heart rate, particularly in neonates.

4. Transport Systems (Transporters)

Drugs can inhibit the transport of molecules across cell membranes by acting on specific transport proteins.

Example: Selective serotonin reuptake inhibitors (SSRIs), which inhibit the serotonin transporter and are used for depression.

Transporters also play a role in drug passage into breast milk (e.g. certain ABC transporters at the mammary epithelium). In lactology, this is relevant because transporter‑mediated movement can increase or decrease drug concentrations in milk and thereby modulate infant exposure. For SSRIs, infant monitoring focuses on potential pharmacodynamic effects such as irritability, poor weight gain or sleep disturbances, although many SSRIs are generally considered compatible with breastfeeding with appropriate surveillance.

5. Other Targets: DNA/RNA and Structural Proteins

Some drugs act directly on nucleic acids (DNA/RNA), especially antineoplastic agents. Others target structural proteins such as microtubules.

These drugs usually have profound pharmacodynamic effects and a narrow therapeutic window, which is why many cytotoxic agents are contraindicated in breastfeeding. The potential for genotoxic or cytotoxic effects in the infant, even at low exposures, leads to strict recommendations to avoid breastfeeding or to temporarily discontinue it during such therapies.

III. Receptor Theory – The Basics

The “key and lock” concept: The drug (ligand) binds specifically to the receptor “pocket”, similar to a key fitting into a lock.

Key parameters:

• Affinity: The strength with which a ligand binds to a receptor. High affinity means tight binding.
• Intrinsic activity (efficacy): The ability of the ligand, once bound, to trigger a conformational change in the receptor that leads to a biological response. This is essential for understanding agonists and antagonists.
• Receptor reserve: A phenomenon where maximal response does not require full occupancy of all receptors. Some agonists can produce maximum effect even when they occupy only a fraction of available receptors.

For lactation pharmacology, high‑affinity, high‑efficacy drugs may elicit strong effects even at low concentrations. If such a drug is well transferred into milk and orally absorbed by the infant, clinically relevant pharmacodynamic responses can occur, prompting cautious dosing, timing relative to feeds, or selection of alternative medications with lower potency or infant exposure.

IV. Drugs as Receptor Agonists and Antagonists

Agonists

What do they do? Agonists bind to receptors and activate them, possessing high intrinsic activity, and thus mimic the action of the natural ligand.

Result: They produce a biological response equivalent or similar to that triggered by the endogenous signal.

Types of agonists:

• Full agonist: Binds and maximally activates the receptor, with high efficacy, generating the maximal biological response.
• Partial agonist: Binds and activates the receptor but with lower efficacy, producing only a partial response even at full receptor occupancy. It can behave functionally as an antagonist in the presence of a full agonist, because it occupies receptors without delivering full effect.
• Inverse agonist: Binds to a constitutively active receptor and reduces its basal activity, thereby lowering the baseline signal.

In breastfeeding medicine, full agonists with central nervous system activity (e.g. strong opioids or sedative hypnotics) may cause oversedation or respiratory depression in the infant if transferred in significant amounts. Partial agonists (such as certain opioid partial agonists) may still cause sedation but often have a ceiling effect, which can be considered in risk assessment. Inverse agonists at histamine or GABA‑related receptors can alter sleep architecture or reduce baseline CNS activity, again requiring infant monitoring.

Antagonists

What do they do? Antagonists bind to receptors without activating them (they have zero intrinsic activity). They block the receptor and prevent binding of agonists, whether endogenous or drug‑derived.

Result: They decrease or abolish the biological response produced by agonists.

Mechanistic types of antagonists:

1. Competitive antagonists
• Bind at the same site as the agonist (the active site).
• The blockade is reversible.
• Surmountable: Higher doses of agonist can “displace” the antagonist and restore the response. The dose–response curve of the agonist shifts to the right.
2. Non‑competitive antagonists
• Bind at a different site from the active site but induce a conformational change that prevents the agonist from activating the receptor, even if binding occurs.
• Blockade is often irreversible or very long‑lasting.
• Insurmountable: Higher doses of agonist cannot restore the maximal response. The maximal effect (Emax) of the agonist is reduced.

From a lactology standpoint, antagonists of dopamine (e.g. some antipsychotics) may increase prolactin and foster or re‑establish milk production, which can be either beneficial or problematic depending on the clinical context. Conversely, competitive antagonists of hormonal receptors (e.g. certain anti‑estrogens) may alter the endocrine milieu relevant to lactation. Non‑competitive, long‑acting antagonists can pose prolonged pharmacodynamic effects in the infant if they reach sufficient concentrations, making careful selection and dosing essential.

V. Key Take‑Home Messages and Clinical Relevance

• Pharmacodynamics answers the question “What does the drug do in the body?”.
• Receptors are the most common drug targets, but enzymes, ion channels and transporters are also pivotal.
• Affinity describes binding strength, while intrinsic activity (efficacy) reflects the capacity to activate the receptor and generate a response.
• Agonists bind and activate receptors: full agonists produce maximal effects, partial agonists produce submaximal effects, and inverse agonists decrease basal receptor activity.
• Antagonists bind without activating receptors and thereby block agonist action.
• Competitive antagonists cause reversible blockade and a rightward shift of the agonist dose–response curve, while non‑competitive antagonists reduce the maximal effect (Emax) and are often irreversible.

Clinical relevance: Understanding the type of agonist or antagonist is critical for predicting clinical effects, adjusting doses and estimating the risk of drug interactions. In the breastfeeding context, it also helps anticipate how maternal therapy may influence both the mother (e.g. prolactin, milk volume, let‑down reflex) and the infant (e.g. CNS depression, cardiovascular effects, endocrine changes), guiding safer drug choice, dosing schedules and infant monitoring strategies.